Clinical Study Protocol Phase 2, Randomized Study of CS-1008 in Combination With Sorafenib Compared to Sorafenib Alone as First-Line Systemic Therapy in Subjects With Advanced Hepatocellular Carcinoma
Phase of Trial: Phase II
Latest Information Update: 14 Aug 2017
At a glance
- Drugs Tigatuzumab (Primary) ; Sorafenib
- Indications Liver cancer
- Focus Registrational; Therapeutic Use
- Sponsors Daiichi Sankyo Inc
- 02 Apr 2015 Status changed from active, no longer recruiting to completed, as per ClinicalTrials.gov record.
- 19 Aug 2014 According to the ClinicalTrials.gov record, planned end date changed from 1 Dec 2013 to 1 Dec 2014.
- 08 Aug 2013 Planned end date changed from 1 Sep 2012 to 1 Dec 2013 as reported by ClinicalTrials.gov.